The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET),
and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic …

The aim of this work is to produce recommendations on the management of allogeneic stem
cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic …

Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell
count greater than 25× 109/L, peripheral blood blasts 1% or higher, and constitutional …

Background The JAK2V617F allele has recently been identified in patients with
polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid …

The current document is a revision of the International Working Group-Myeloproliferative
Neoplasms Research and Treatment (IWG-MRT) criteria for treatment response in …

Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current
prognostic scoring systems aim to select patients for transplantation. Here, we aimed to …

BACKGROUND. Few objective data exist on the burden of fatigue and other constitutional
symptoms in patients with myeloproliferative disorders (MPD). METHODS. The authors used …

Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen
at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic …

Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several
small series have reported long-term disease-free survival (DSF) after allogeneic …

Abstract In 1951 William Dameshek classified polycythemia vera (PV), essential
thombocytosis (ET), and primary myelofibrosis (PMF) as pathogenetically related …